ZimVie Inc. (ZIMV) Stock
ZimVie Inc.

Company profile
ZimVie reported revenue of $449.75 million for fiscal year 2024, down 1.7% from fiscal year 2023. In Q2 2025 (the quarter ended June 30, 2025) revenue was $116.66 million, down 0.1% from a year before. United States was its largest region in fiscal year 2024, with 59% of revenue. In Q2 2025 it reported a net loss of $3.95 million, against a net loss of $4.01 million a year earlier. Our analysis of its filings shows revenue shrinking from $463.29 million in fiscal year 2022 to $449.75 million in fiscal year 2024, 1.5% a year on average. ZimVie reports about 1,770 full-time employees.
What stands out
- It reported a net loss in each of its last 5 fiscal years; the loss narrowed from $393.28 million in fiscal year 2023 to $25.83 million in fiscal year 2024.
Figures from company filings; latest fiscal year ended December 31, 2024.
About ZimVie Inc.
ZimVie Inc., together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to support dental tooth replacement and restoration procedures worldwide. The company offers dental implant systems and biomaterials; digital dentistry solutions; restorative and abutment products, surgical instrumentation, and kits; and patient-specific restorative solutions, such as abutments, bars, implant bridges, and hybrid restorations under the BellaTek brand name. It provides bone grafts, barrier membranes, and collagen wound care products; virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and intra-oral scanners; intraoral scanners; and Implant Concierge, a web-based treatment planning and surgery guide service. The company sells its products to oral surgeons, dental specialists, general dentists, dental laboratories, and other dental organizations, including dental service organizations, as well as educational, medical and governmental entities, hospitals, and surgery centers through sales representatives, independent sales agents, and distributors. ZimVie Inc. was incorporated in 2021 and is headquartered in Palm Beach Gardens, Florida. As of October 20, 2025, ZimVie Inc. was taken private.
Leadership
- Vafa Jamali — President, CEO & Chairman of the Board, 54
- Richard J. Heppenstall — Executive VP, CFO & Treasurer, 53
- Heather Kidwell — Senior VP, Chief Legal, HR & Compliance Officer and Corporate Secretary, 55
- Indraneel Kanaglekar — Senior VP & Chief Commercial Officer, 46
- Sandra Schneider — Chief Accounting Officer
In the news
- ZimVie Stockholders Vote to Approve Acquisition by ARCHIMED
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ZIMV, ARIS, SCPH on Behalf of Shareholders
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ZIMV, DALN, VBTX, GNTY on Behalf of Shareholders
- $HAREHOLDER ALERT: The M&A Class Action Firm Encourages $hareholders to Act Before the Vote
How much revenue does ZimVie make?
ZimVie reported $449.75 million in revenue for fiscal year 2024, down 1.7% from $457.43 million in fiscal year 2023. In Q2 2025 revenue was $116.66 million.
Where does ZimVie make most of its revenue?
United States: 59% of revenue by region in fiscal year 2024, followed by Other Countries (30%).
What companies are similar to ZimVie?
Listed companies of a similar size in the same industry (targeted healthcare equipment) include Senzime AB (publ) (SEZI.ST), Lumibird SA (LBIRD.PA), Bactiguard Holding AB (publ) (BACTI-B.ST), Ion Beam Applications SA (IBAB.BR).
Has ZimVie made a profit in recent years?
Net income by fiscal year: FY2020, a loss of $179.09 million; FY2021, a loss of $95.25 million; FY2022, a loss of $63.88 million; FY2023, a loss of $393.28 million; FY2024, a loss of $25.83 million. It reported a net loss in each of these 5 years.
Data as of .
How to cite: DataPorium, “ZimVie Inc. (ZIMV)”, data as of Jun 30, 2025, https://dataporium.tech/stocks/ZIMV